Melanotan II Injections Linked to Oral Mucosa Changes in Case Report
Background
Melanotan II is an unregulated synthetic peptide, a cyclic lactam derivative (Ac-Nle-α-MSH-NH2) designed to mimic α-melanocyte-stimulating hormone (α-MSH). It activates MC1-R receptors on melanocytes, promoting eumelanin production for a tanned appearance. While its use is increasing despite being illegal in many countries, there's a known association with cutaneous melanoma (skin cancer), though a direct causal link remains unconfirmed. Previous reports have also linked Melanotan II to intraoral pigmentation and even a potential case of intraoral melanoma from nasal spray use. This case report specifically investigates and documents changes in the oral mucosa associated with Melanotan II injections, addressing the limited understanding of its direct intraoral effects from injectable forms.
Results
The full case report, building upon existing literature, documented specific alterations in the oral mucosa of the individual using Melanotan II injections. These observed changes are consistent with the known melanogenic (melanin-producing) effects of the peptide, indicating that its pigmentary influence extends to non-cutaneous tissues within the oral cavity. Previous research has already highlighted an association between Melanotan II use and intraoral pigmentation, suggesting a broader systemic impact. Notably, one prior report described a case of intraoral melanoma potentially linked to the use of Melanotan II via nasal spray. The case report identified distinct changes in the oral mucosa of a Melanotan II user, reinforcing concerns about the peptide's systemic effects and potential for intraoral pigmentation.
Why It Matters
This case report is significant as it highlights the potential for adverse effects of Melanotan II beyond the skin, specifically within the oral cavity, from injectable use. It adds to the growing body of evidence suggesting that unregulated tanning peptides can induce systemic changes, including intraoral pigmentation, which could potentially mask or contribute to more serious conditions like oral melanoma. The findings underscore the critical importance of increased awareness among healthcare professionals and the public regarding the risks associated with unregulated substances like Melanotan II, particularly for oral health. Further research, including larger observational studies and potentially human trials, is needed to fully characterize the prevalence and long-term implications of these oral changes.